Compare AMC & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMC | TYRA |
|---|---|---|
| Founded | 1920 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 2007 | 2021 |
| Metric | AMC | TYRA |
|---|---|---|
| Price | $2.60 | $25.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $2.03 | ★ $47.50 |
| AVG Volume (30 Days) | ★ 18.1M | 518.6K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,848,900,000.00 | N/A |
| Revenue This Year | $11.41 | N/A |
| Revenue Next Year | $5.18 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 4.57 | N/A |
| 52 Week Low | $0.93 | $11.82 |
| 52 Week High | $3.18 | $40.65 |
| Indicator | AMC | TYRA |
|---|---|---|
| Relative Strength Index (RSI) | 54.02 | 43.11 |
| Support Level | $2.32 | $24.72 |
| Resistance Level | $3.00 | $27.02 |
| Average True Range (ATR) | 0.14 | 0.96 |
| MACD | -0.01 | 0.11 |
| Stochastic Oscillator | 61.41 | 59.35 |
AMC Entertainment Holdings Inc is involved in the theatrical exhibition business. The company owns, operates, or has interests in theatres located in the United States and Europe. It provides amenities such as plush, power recliners, MacGuffins full bars, AMC Dine-In Theatres, and premium presentation. The company has identified two reportable segments and reporting units for its theatrical exhibition operations, U.S. markets and International markets. It derives key revenue from the U.S.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.